Pfizer’s ‘most favored nation’ deal; Metsera’s obesity data; Takeda stops cell therapy work; and more
Article Title: Pfizer’s ‘most favored nation’ deal; Metsera’s obesity data; Takeda stops cell therapy work; and more Publication Date: October 4, 2025 This week, Endpoints Weekly brings us several emerging stories that strategically impact the biotech arena. Several key players…